Healthy Volunteers
Conditions
Keywords
UV-A irradiation, Cyclobutane-Pyrimidine Dimer, Oxidative lesions, cutaneous phototype, UV-B irradiation, DNA damages
Brief summary
The DIMUVA study aims to evaluate the correlation between cutaneous phototype and the nature and quantity of damage caused to cutaneous DNA after exposure to UV-A radiation.
Detailed description
Due to their capacity to damage Deoxyribonucleic acid (DNA), Ultra-Violet (UV) radiation is one of the causes of skin cancers. Until recently, the genotoxic effects of UV-A radiation, were poorly identified, in particular their capacity to lead to the dimerization of pyrimidine bases . It is well known that the response to UV-A and UV-B radiations is different depending on the cutaneous phototype. Thus, the aim of this study is to determine the correlation between cutaneous phototype and the quantity and nature (CPD or oxidative lesions) of damage caused to cutaneous DNA after an ex-vivo exposure to UV-A and UV-B radiations.
Interventions
RADIATIONUVA and UVB irradiation
* 4 cutaneous biopsies for Ex-vivo irradiation * Determination of the minimal erythemic dose of UVA and UVB for each volunteer
Sponsors
Commissariat A L'energie Atomique
University Hospital, Grenoble
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Male, * Between 18 and 35 years old, * Healthy volunteers, * Cutaneous phototype 2 or 4 according to the Fitzpatrick classification, * Affiliation to the French Social Security.
Exclusion criteria
* History of photosensibility, * Active smoking or stopped since less than one year, * Dermatological pathology or treatment contra-indicating cutaneous irradiation and skin biopsies, * Any chronic pathology susceptible to interfere with the evaluations related to the protocol, * Allergy to local anaesthetics, * Volunteers who take drugs and/or food complements acting on oxidative stress in the 8 weeks preceding inclusion, * Volunteers who have take paracetamol or aspirin within 7 days prior to the inclusion visit, * Subject in exclusion period for another biomedical research study, * Subject having exceeded the threshold of annual compensation for biomedical research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phototype determination according to the Fitzpatrick classification Number of CPD and oxidative lesions determinated by the analysis of DNA from the skin biopsies after their ex-vivo exposure to UV-A - The CPD / Oxidative lesions ratio | Day 0 |
Secondary
| Measure | Time frame |
|---|---|
| Number of CPD and oxidative lesions determinated by the analysis of DNA from the skin biopsies after their exposure ex-vivo to UV-B. | Day 0 |
| UV-A radiation exposure: Minimal erythemic dose - Number of CPD and oxidative lesions - CPD / oxidative lesions ratio | Day x |
| UV-B radiation exposure: Minimal erythemic dose - Number of CPD and oxidative lesions - CPD/oxidative lesions ratio | Day 0 |
| antioxidant status and quantity of CPD, oxidative lesions after exposure to UV-A and UV-B radiations | day 2 |
Countries
France
Outcome results
None listed